Day Two | 17th April
- What is the projected size and makeup (autologous/allogeneic cell gene therapies, targeted mRNA, immunotherapy etc) of the personalised therapies market by 2030 and it’s impact upon supply chains?
- What are the demands upon the supply chain of these therapies and what are the implications of these demands in terms of planning, value chain management, distribution, quality and enterprise cohesion?
- How can the industry best meet the challenges associated with scale up and commercial viability of drug supply?
- Why must producers drive close connections with patients, HCPs and with one another in order to enable success?
Check out the incredible speaker line-up to see who will be joining Tamas.
Download The Latest Agenda